Advancing pharmacogenetic testing in a tertiary hospital: a retrospective analysis after 10 years of activity
The field of pharmacogenetics (PGx) holds great promise in advancing personalized medicine by adapting treatments based on individual genetic profiles. Despite its benefits, there are still economic, ethical and institutional barriers that hinder its implementation in our healthcare environment. A retrospective analysis approach of anonymized data sourced from electronic health records was performed, encompassing a diverse patient population and evaluating key parameters such as prescribing patterns and test results, to assess the impact of pharmacogenetic testing. A head-to-head comparison with previously published activity results within the same pharmacogenetic laboratory was also conducted to contrast the progress made after 10 years. The analysis revealed significant utilization of pharmacogenetic testing in daily clinical practice, with 1,145 pharmacogenetic tests performed over a 1-year period and showing a 35% growth rate increase over time. Of the 17 different medical departments that sought PGx tests, the Oncology department accounted for the highest number, representing 58.47% of all genotyped patients. A total of 1,000 PGx tests were requested for individuals susceptible to receive a dose modification based on genotype, and 76 individuals received a genotype-guided dose adjustment. This study presents a comprehensive descriptive analysis of real-world data obtained from a public tertiary hospital laboratory specialized in pharmacogenetic testing, and presents data that strongly endorse the integration of pharmacogenetic testing into everyday clinical practice..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Frontiers in Pharmacology - 14(2023) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Stefan Stewart [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Personalized medicine |
|---|
| doi: |
10.3389/fphar.2023.1292416 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ091547881 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ091547881 | ||
| 003 | DE-627 | ||
| 005 | 20240412095651.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240412s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fphar.2023.1292416 |2 doi | |
| 035 | |a (DE-627)DOAJ091547881 | ||
| 035 | |a (DE-599)DOAJ8d142befa8af47ffaafc39bc0315062c | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RM1-950 | |
| 100 | 0 | |a Stefan Stewart |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Advancing pharmacogenetic testing in a tertiary hospital: a retrospective analysis after 10 years of activity |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The field of pharmacogenetics (PGx) holds great promise in advancing personalized medicine by adapting treatments based on individual genetic profiles. Despite its benefits, there are still economic, ethical and institutional barriers that hinder its implementation in our healthcare environment. A retrospective analysis approach of anonymized data sourced from electronic health records was performed, encompassing a diverse patient population and evaluating key parameters such as prescribing patterns and test results, to assess the impact of pharmacogenetic testing. A head-to-head comparison with previously published activity results within the same pharmacogenetic laboratory was also conducted to contrast the progress made after 10 years. The analysis revealed significant utilization of pharmacogenetic testing in daily clinical practice, with 1,145 pharmacogenetic tests performed over a 1-year period and showing a 35% growth rate increase over time. Of the 17 different medical departments that sought PGx tests, the Oncology department accounted for the highest number, representing 58.47% of all genotyped patients. A total of 1,000 PGx tests were requested for individuals susceptible to receive a dose modification based on genotype, and 76 individuals received a genotype-guided dose adjustment. This study presents a comprehensive descriptive analysis of real-world data obtained from a public tertiary hospital laboratory specialized in pharmacogenetic testing, and presents data that strongly endorse the integration of pharmacogenetic testing into everyday clinical practice. | ||
| 650 | 4 | |a pharmacogenetic dosing | |
| 650 | 4 | |a preemptive genotyping | |
| 650 | 4 | |a real-world data | |
| 650 | 4 | |a personalized medicine | |
| 650 | 4 | |a retrospective analysis | |
| 653 | 0 | |a Therapeutics. Pharmacology | |
| 700 | 0 | |a Jose Manuel Dodero-Anillo |e verfasserin |4 aut | |
| 700 | 0 | |a Javier Guijarro-Eguinoa |e verfasserin |4 aut | |
| 700 | 0 | |a Pedro Arias |e verfasserin |4 aut | |
| 700 | 0 | |a Arturo Gómez López De Las Huertas |e verfasserin |4 aut | |
| 700 | 0 | |a Enrique Seco-Meseguer |e verfasserin |4 aut | |
| 700 | 0 | |a Irene García-García |e verfasserin |4 aut | |
| 700 | 0 | |a Elena Ramírez García |e verfasserin |4 aut | |
| 700 | 0 | |a Elena Ramírez García |e verfasserin |4 aut | |
| 700 | 0 | |a Carlos Rodríguez-Antolín |e verfasserin |4 aut | |
| 700 | 0 | |a Antonio J. Carcas |e verfasserin |4 aut | |
| 700 | 0 | |a Antonio J. Carcas |e verfasserin |4 aut | |
| 700 | 0 | |a Sonia Rodriguez-Novoa |e verfasserin |4 aut | |
| 700 | 0 | |a Rocio Rosas-Alonso |e verfasserin |4 aut | |
| 700 | 0 | |a Rocio Rosas-Alonso |e verfasserin |4 aut | |
| 700 | 0 | |a Alberto M. Borobia |e verfasserin |4 aut | |
| 700 | 0 | |a Alberto M. Borobia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Frontiers in Pharmacology |d Frontiers Media S.A., 2010 |g 14(2023) |w (DE-627)DOAJ000099732 |x 16639812 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fphar.2023.1292416 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/8d142befa8af47ffaafc39bc0315062c |z kostenfrei |
| 856 | 4 | 0 | |u https://www.frontiersin.org/articles/10.3389/fphar.2023.1292416/full |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1663-9812 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 | ||